ICHG 2024 7
Networking News Briefs

Global Experts Gather for ICHG 2024 to Advance Hyperemesis Gravidarum (HG) Research and Care 

The 2024 International Colloquium on Hyperemesis Gravidarum (ICHG) takes place November 6-7 in Ventura, CA. The two-day event brings together the world’s leading researchers, clinicians, Hyperemesis Gravidarum (HG) charities and patient advocates for the advancement of scientific research and the promotion of clinical excellence in treating the condition.

The Hyperemesis Education and Research (HER) Foundation is hosting the ICHG 2024. Sessions feature thirty speakers from four continents and twenty-five poster presentations. All highlight the latest research developments and innovative treatments for the complex pregnancy disease, HG.

ICHG 2024 agenda features 30 international speakers

The international speakers will share breakthrough research on HG and will discuss how to conduct novel clinical trials on HG. Other sessions will focus on needed improvements in clinical practice with a particular focus on drafting the first nutritional guidelines. All sessions will foster participation from researchers, clinicians and patients. Other speakers and special breakout sessions will focus on needed improvements in clinical practice. This work includes collaboratively drafting the first international nutritional guidelines for HG. Posters will be displayed on both days and time for presentation will be given. An interesting and relevant exhibition of sponsors from the commercial and charity sectors will provide additional interest. 

ICHG 2024 conference sessions include:

  • Genetics and science behind HG
  • Clinical trials results and challenges
  • Nutritional needs, risks, and guidelines
  • Improving patient experience
  • Networking opportunities
  • Difficult cases
  • Cannabis and HG
  • Anti-bias training

About Hyperemesis Gravidarum (HG)

Hyperemesis Gravidarum is a potentially life-threatening pregnancy disease affecting 1-10 percent of pregnancies or at least 2 million mothers annually. Inadequate management leads to potentially life-threatening complications for mother and baby, with 1 in 3 pregnancies ending in fetal loss or preterm birth. 

  • HG is the leading cause of hospitalization in early pregnancy and the second cause overall. 
  • HG causes an increased risk of premature delivery, restricted fetal growth and placental disorders such as preeclampsia. 
  • Children born after an HG pregnancy have an increased risk of autism and a 3-10-fold increase in neurodevelopmental, sensory and behavioral disorders. 
  • Research demonstrates that health providers do not recognize the seriousness of HG, thus limiting or delaying treatment (Munch, 2002). This contributes to the development of trauma, anxiety and depression (Poursharif, 2008; Christodoulou-Smith, 2011). And this leads to therapeutic termination, job loss and changes in family plans. 
  • Learn more about HG. 

About HER Foundation

Founded in 2002, the HER Foundation is a global nonprofit that aims to increase awareness of HG and provide support, education, research and advocacy. The Foundation’s genetic research has changed the understanding of Hyperemesis Gravidarum (HG). We aim to find a cure through collaborative research, provide tools and education for HG management, advocate for HG sufferers and effect change through policy. We have helped millions of women suffering and recovering from HG, grieving the loss of their children and preparing for pregnancy. HER maintains the leading website on HG, including treatment protocols, assessment tools and HG Care iOS app. Our treatment protocols, assessment tools and the HG Care iOS app give mothers and babies a chance at a healthy future.

About the International Collaboration on Hyperemesis Gravidarum (ICHG) 

The International Collaboration on Hyperemesis Gravidarum (ICHG) aligns with international charities whose purpose and mission is to improve care, treatment and support for those suffering from nausea and vomiting in pregnancy (NVP) and the severe form of the condition; hyperemesis gravidarum (HG). ICHG collaborates with clinicians, researchers and experts in the field. The organization seeks to facilitate, encourage and support further research into HG, its impacts and its treatments. We enable the voices of people with HG to be heard within the research process. Our biennial conferences provides the opportunity for delegates to hear about the latest research developments and innovative treatments for this complex condition. 

Learn more about HG research and advocacy in our interviews with Marlena Fejzo, PhD, and Elizabeth Franklin.

Check for errors 160x600 1

©Innovation Women LLC 2024

Innovation Women ® is a registered trademark of Innovation Women LLC